Showing results (191-200 of 205) with videos related to
Sort By:
Pageof 21
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 8, 2001
Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patientsA Di Paolo, R Danesi, A Falcone, et al.Experimental Eye Research|September 12, 1998
The heparan sulfate suleparoide inhibits rat corneal angiogenesis and in vitro neovascularizationU Benelli, G Bocci, R Danesi, et al.Neurogastroenterology and Motility|August 22, 2006
Constitutive expression of cyclooxygenase-2 in the neuromuscular compartment of normal human colonN Bernardini, R Colucci, L Mattii, et al.Cancer Chemotherapy and Pharmacology|October 8, 2008
A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancerLorenzo Fornaro, G Masi, S Bursi, et al.Bone Marrow Transplantation|March 7, 2003
High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding studyC Bengala, R Danesi, V Guarneri, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2000
Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patientsG Bocci, R Danesi, A D Di Paolo, et al.The Journal of Clinical Endocrinology and Metabolism|June 1, 1996
Clinical and experimental evidence of inhibition of testosterone production by suraminR Danesi, R V La Rocca, M R Cooper, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 16, 2001
High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC)C Bengala, I Pazzagli, F Innocenti, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1997
Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancerP F Conte, E Baldini, A Gennari, et al.British Journal of Cancer|April 30, 2008
Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinibG Bocci, A Falcone, A Fioravanti, et al.Pageof 21